Zacks Research Weighs in on Editas Medicine FY2027 Earnings

Editas Medicine, Inc. (NASDAQ:EDIT) – Stock analysts at Zacks Research issued their FY2027 EPS estimates for shares of Editas Medicine in a research note issued to investors on Wednesday, March 26th. Zacks Research analyst A. Chakraborty forecasts that the company will post earnings per share of ($2.30) for the year. The consensus estimate for Editas Medicine’s current full-year earnings is ($2.71) per share.

Editas Medicine (NASDAQ:EDIT) last issued its quarterly earnings data on Wednesday, March 5th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.16). Editas Medicine had a negative net margin of 340.96% and a negative return on equity of 80.13%. The company had revenue of $30.60 million for the quarter, compared to the consensus estimate of $37.17 million. During the same quarter last year, the company earned ($0.23) EPS.

A number of other research analysts also recently weighed in on EDIT. Robert W. Baird lowered their target price on Editas Medicine from $10.00 to $8.00 and set an “outperform” rating on the stock in a report on Friday, December 13th. Stifel Nicolaus lowered shares of Editas Medicine from a “buy” rating to a “hold” rating and cut their target price for the company from $11.00 to $3.00 in a research report on Friday, December 13th. Chardan Capital reaffirmed a “neutral” rating on shares of Editas Medicine in a report on Friday, December 13th. Barclays dropped their price target on shares of Editas Medicine from $5.00 to $3.00 and set an “equal weight” rating on the stock in a research note on Friday, December 13th. Finally, Royal Bank of Canada reduced their price objective on Editas Medicine from $5.00 to $4.00 and set a “sector perform” rating for the company in a research note on Friday, December 13th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $6.83.

Editas Medicine Price Performance

NASDAQ EDIT opened at $1.30 on Friday. The stock has a market capitalization of $107.87 million, a price-to-earnings ratio of -0.51 and a beta of 1.88. Editas Medicine has a 1-year low of $1.12 and a 1-year high of $7.52. The business’s fifty day moving average price is $1.51 and its 200-day moving average price is $2.20.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Jacobs Levy Equity Management Inc. raised its position in shares of Editas Medicine by 133.2% during the third quarter. Jacobs Levy Equity Management Inc. now owns 529,834 shares of the company’s stock valued at $1,807,000 after buying an additional 302,652 shares during the last quarter. Barclays PLC lifted its position in shares of Editas Medicine by 46.9% in the third quarter. Barclays PLC now owns 178,507 shares of the company’s stock worth $607,000 after buying an additional 56,986 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in Editas Medicine by 37.3% during the third quarter. BNP Paribas Financial Markets now owns 54,787 shares of the company’s stock valued at $187,000 after buying an additional 14,888 shares during the last quarter. FMR LLC grew its holdings in Editas Medicine by 110.7% during the 3rd quarter. FMR LLC now owns 203,087 shares of the company’s stock valued at $693,000 after buying an additional 106,684 shares in the last quarter. Finally, Monaco Asset Management SAM bought a new stake in Editas Medicine in the 4th quarter worth approximately $1,359,000. 71.90% of the stock is owned by hedge funds and other institutional investors.

Editas Medicine Company Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.